
Ekaterina V Belik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9094350/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adipokine gene expression in adipocytes isolated from different fat depots of coronary artery disease patients. Archives of Physiology and Biochemistry, 2022, 128, 261-269.	1.0	8
2	Relationship between Epicardial and Coronary Adipose Tissue and the Expression of Adiponectin, Leptin, and Interleukin 6 in Patients with Coronary Artery Disease. Journal of Personalized Medicine, 2022, 12, 129.	1.1	21
3	Effects of Physical Prehabilitation on the Dynamics of the Markers of Endothelial Function in Patients Undergoing Elective Coronary Bypass Surgery. Journal of Personalized Medicine, 2022, 12, 471.	1.1	4
4	Features of plasminogen activator inhibitor-1 synthesis by local fat depots of different localization in cardiovascular diseases. Russian Journal of Cardiology, 2022, 27, 4866.	0.4	1
5	Features of plasminogen activator inhibitor-1 synthesis by local fat depots of different localization in cardiovascular diseases. Russian Journal of Cardiology, 2022, 27, 4866.	0.4	Ο
6	Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction. Russian Journal of Cardiology, 2021, 26, 4137.	0.4	0
7	Expression of adipocytokines in heart fat depots depending on the degree of coronary artery atherosclerosis in patients with coronary artery disease. PLoS ONE, 2021, 16, e0248716.	1.1	6
8	Associations of adipocytokine expression and cardiovascular risk factors in stable coronary artery disease. Russian Journal of Cardiology, 2021, 26, 4318.	0.4	0
9	Expression of adipocytokine in heart fat depots depending on the degree of coronary artery atherosclerosis in patients with coronary artery disease. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 159-168.	0.2	1
10	Relationships between the expression of adipocytokine genes and the calcification of coronary arteries in patients with coronary artery disease. Sibirskij žurnal KliniÄeskoj I èksperimentalʹnoj Mediciny, 2021, 36, 68-77.	0.1	0
11	Possibilities of neurocognitive rehabilitation using the dual tasks method in patients in the early postoperative period of coronary bypass surgery. Cardiosomatics, 2021, 12, 200-205.	0.2	2
12	Relationship of visceral obesity and coronary calcinosis in ischemic heart disease. Terapevticheskii Arkhiv, 2021, 93, 1428-1434.	0.2	0
13	Predictors of myocardial fibrosis and loss of epicardial adipose tissue volume in the long-term period after myocardial infarction. Russian Journal of Cardiology, 2020, 25, 31-40.	0.4	4
14	Insulin resistance: Unsolved issues of harm and use. Siberian Medical Journal, 2020, 34, 39-48.	0.3	0
15	Ceramides: focus on obesity. Obesity and Metabolism, 2020, 17, 307-315.	0.4	2
16	Visceral adiposity index in patients with coronary artery disease, obesity and type 2 diabetes. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2311.	0.4	2
17	Adiponectin and insulin: molecular mechanisms of metabolic disorders. Bulletin of Siberian Medicine, 2020, 19, 188-197.	0.1	1
18	The relationship of the epicardial fat and adipo-fibrokines in myocardial infarction. Klinichescheskaya Laboratornaya Diagnostika, 2020, 65, 533-540.	0.2	1

Ekaterina V Belik

#	ARTICLE	IF	CITATIONS
19	Key factors of inflammation and long-term prognosis in patients with myocardial infarction and visceral obesity. Pacific Medical Journal, 2020, , 77-82.	0.0	0
20	Adipocytes Directly Affect Coronary Artery Disease Pathogenesis via Induction of Adipokine and Cytokine Imbalances. Frontiers in Immunology, 2019, 10, 2163.	2.2	24
21	The role of immune cells in the development of adipose tissue dysfunction in cardiovascular diseases. Russian Journal of Cardiology, 2019, , 92-98.	0.4	3
22	The role of newly diagnosed diabetes mellitus for poor in-hospital prognosis of coronary artery bypass grafting. Diabetes Mellitus, 2018, 21, 344-355.	0.5	7
23	Leptin resistance: unsolved diagnostic issues. Problemy Endokrinologii, 2018, 64, 62-66.	0.2	7
24	Leptin resistance: unsolved diagnostic issues. Problemy Endokrinologii, 2018, 64, 62-66.	0.2	0
25	Biochemical markers of type 2 diabetes as a late complication of myocardial infarction: a case-control study. Archives of Medical Science, 2017, 2, 311-320.	0.4	10
26	Prognostic Value of Soluble ST2 During Hospitalization for ST-Segment Elevation Myocardial Infarction. Annals of Laboratory Medicine, 2016, 36, 313-319.	1.2	17
27	The role of adipose tissue and adipokines in the manifestation of type 2 diabetes in the long-term period following myocardial infarction. Diabetology and Metabolic Syndrome, 2016, 8, 24.	1.2	17
28	Dose-dependent effects of atorvastatin on myocardial infarction. Drug Design, Development and Therapy, 2015, 9, 3361.	2.0	8
29	Lipid, adipokine and ghrelin levels in myocardial infarction patients with insulin resistance. BMC Cardiovascular Disorders, 2014, 14, 7.	0.7	18
30	Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction. Lipids in Health and Disease, 2014, 13, 111.	1.2	23
31	Insulin resistance and inflammation markers in myocardial infarction. Journal of Inflammation Research, 2013, 6, 83.	1.6	22
32	Relationship between free fatty acids, insulin resistance markers, and oxidized lipoproteins in myocardial infarction and acute left ventricular failure. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, 6, 103.	1.1	12
33	Plasminogen activator inhibitor-1, free fatty acids, and insulin resistance in patients with myocardial infarction. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, 6, 293.	1.1	8